1. Home
  2. LCTX vs CMCM Comparison

LCTX vs CMCM Comparison

Compare LCTX & CMCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • CMCM
  • Stock Information
  • Founded
  • LCTX 1990
  • CMCM 2009
  • Country
  • LCTX United States
  • CMCM China
  • Employees
  • LCTX N/A
  • CMCM N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • CMCM Computer Software: Prepackaged Software
  • Sector
  • LCTX Health Care
  • CMCM Technology
  • Exchange
  • LCTX Nasdaq
  • CMCM Nasdaq
  • Market Cap
  • LCTX 107.3M
  • CMCM 115.1M
  • IPO Year
  • LCTX N/A
  • CMCM 2014
  • Fundamental
  • Price
  • LCTX $0.70
  • CMCM $4.10
  • Analyst Decision
  • LCTX Strong Buy
  • CMCM
  • Analyst Count
  • LCTX 5
  • CMCM 0
  • Target Price
  • LCTX $4.20
  • CMCM N/A
  • AVG Volume (30 Days)
  • LCTX 1.5M
  • CMCM 23.5K
  • Earning Date
  • LCTX 08-07-2025
  • CMCM 06-24-2025
  • Dividend Yield
  • LCTX N/A
  • CMCM N/A
  • EPS Growth
  • LCTX N/A
  • CMCM N/A
  • EPS
  • LCTX N/A
  • CMCM N/A
  • Revenue
  • LCTX $9,557,000.00
  • CMCM $110,544,725.00
  • Revenue This Year
  • LCTX N/A
  • CMCM $14.27
  • Revenue Next Year
  • LCTX $232.66
  • CMCM $39.26
  • P/E Ratio
  • LCTX N/A
  • CMCM N/A
  • Revenue Growth
  • LCTX 19.42
  • CMCM 20.52
  • 52 Week Low
  • LCTX $0.37
  • CMCM $3.02
  • 52 Week High
  • LCTX $1.15
  • CMCM $6.77
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 62.72
  • CMCM 46.78
  • Support Level
  • LCTX $0.48
  • CMCM $4.01
  • Resistance Level
  • LCTX $0.83
  • CMCM $4.45
  • Average True Range (ATR)
  • LCTX 0.06
  • CMCM 0.25
  • MACD
  • LCTX 0.01
  • CMCM -0.03
  • Stochastic Oscillator
  • LCTX 60.76
  • CMCM 30.43

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About CMCM Cheetah Mobile Inc. each representing fifty (50)

Cheetah Mobile Inc along with its subsidiaries provides comprehensive products and services on PCs and mobile devices. It generates revenue from utility-related business, including advertising services and premium membership services. It also provides multi-cloud management platform and overseas advertising agency service. The company operates in two segments: Internet business, and AI and others. The firm's majority of the revenue is derived from the internet business segment that provides mobile advertising services to advertising customers, as well as selling advertisements and referring user traffic on its mobile and PC platforms. Geographically, it derives the majority of its revenue from the PRC and the rest from Hong Kong, Japan, and the rest of the world.

Share on Social Networks: